Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jun 25;3(3):e000790. doi: 10.1161/JAHA.114.000790

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Figure 4. — Short‐axis, mid‐level sections of cardiac tissue from the left ventricle (LV) in mice treated with l‐NAME (A and C), and spironolactone and l‐NAME (B and D), after 7 weeks of l‐NAME. Short‐axis sections stained with Masson's trichrome stains in (A) and (B) illustrate relative abundant interstitial fibrosis (appearing blue) in l‐NAME, as compared to l‐NAME+spironolactone. Adjacent slices in the same mice in (C) and (D) were stained with fluorescein isothiocyanate‐conjugated (FITC) wheat germ agglutinin to delineate cell membranes. With l‐NAME alone, mice showed cardiomyocyte hypertrophy, compared to l‐NAME+spironolactone. The cardiomyocyte diameters in the anterior, lateral, inferior and septal LV segments were significantly larger in l‐NAME compared to l‐NAME+spironolactone (P<0.001). l‐NAME indicates Nω–nitro‐l‐arginine‐methyl‐ester.